LETTERS TO THE EDITOR

Por Slingluff, Craig L.
Publicado em 1995

Current Surgical Therapy (5th Edition)

Por Slingluff, Craig L.
Publicado em 1996

The Present and Future of Peptide Vaccines for Cancer: Single or Multiple, Long or Short, Alone or in Combination?

Por Slingluff, Craig L.
Publicado em 2011

Short Length of Stay and Rapid Recovery to Normal Function after Surgery for Metastatic Melanoma to Abdominal and Retroperitoneal Viscera

Por Dengel, Lynn T., Slingluff, Craig L.
Publicado no J Surg Oncol (2009)

Progress and controversies in developing cancer vaccines

Por Slingluff, Craig L, Speiser, Daniel E
Publicado em 2005

Letters to the Editor

Por Slingluff, Craig L., Seigler, H.F.
Publicado em 1989

Regional control and morbidity after superficial groin dissection in melanoma

Por Shada, Amber L., Slingluff, Craig L.
Publicado no Ann Surg Oncol (2010)

TLR2/6 agonists and IFN-gamma treatment induces favorable immune cell recruiting signatures from melanoma associated with STAT1 and IL-32 signaling

Por Mauldin, Ileana S, Slingluff, Craig L, Wang, Ena
Publicado no J Immunother Cancer (2014)

Localization of the sentinel lymph node in melanoma without blue dye

Por Hu, Yinin, Melmer, Patrick D., Slingluff, Craig L.
Publicado no Ann Surg (2016)

Vaccines, adjuvants and dendritic cell activators – Current Status and Future Challenges

Por Obeid, Joseph M., Hu, Yinin, Slingluff, Craig L.
Publicado no Semin Oncol (2015)

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin

Por Slingluff Craig L, Brautigan David L, Molhoek Kerrington R
Publicado em 2005-10-01

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin

Por Molhoek, Kerrington R, Brautigan, David L, Slingluff, Craig L
Publicado em 2005

Interface of Signal Transduction Inhibition and Immunotherapy in Melanoma

Por Shada, Amber L., Molhoek, Kerrington R., Slingluff, Craig L.
Publicado em 2010

Antibody response to melanoma helper-peptide vaccine correlates with survival

Por Olson, Walter C, Reed, Caroline M, Slingluff, Craig L
Publicado em 2013

A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma

Por Wages, Nolan A., Slingluff, Craig L., Petroni, Gina R.
Publicado no Contemp Clin Trials (2015)

A Triangular Intermuscular Space Sentinel Node in Melanoma: Association With Axillary Lymphatic Drainage

Por Hennessy, Sara A., Dengel, Lynn T., Hranjec, Tjasa, Slingluff, Craig L.
Publicado em 2010

TLR2/6 agonists and IFNγ synergize to induce melanoma cells to produce T-cell recruiting chemokines

Por Mauldin, Ileana S, Wang, Ena, Deacon, Donna H, Slingluff, Craig L
Publicado em 2013

Defining the effects of age and gender on clinical immune response to cancer vaccination

Por Ramirez, Adriana, Wages, Nolan, Smolkin, Mark E, Slingluff, Craig L
Publicado no J Immunother Cancer (2014)

Utility of Sentinel Lymph Node Biopsy for Solitary Dermal Melanomas

Por Hu, Yinin, Shah, Puja, Stukenborg, George J., Slingluff, Craig L.
Publicado no J Surg Oncol (2015)

Long-Term Outcomes of Helper Peptide Vaccination for Metastatic Melanoma

Por Hu, Yinin, Kim, Helen, Blackwell, Christopher M., Slingluff, Craig L.
Publicado no Ann Surg (2015)